Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. (CPH.TO) Financial Performance & Income Statement Overview
Explore the financials of Cipher Pharmaceuticals Inc. (CPH.TO), including yearly and quarterly data on income, cash flow, and balance sheets.
Cipher Pharmaceuticals Inc. (CPH.TO) Income Statement & Financial Overview
Analyze Cipher Pharmaceuticals Inc.’s CPH.TO earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $12.02M | $11.82M | $10.37M | $5.30M |
| Cost of Revenue | $2.88M | $5.13M | $1.97M | $1.11M |
| Gross Profit | $9.14M | $6.69M | $8.40M | $4.20M |
| Gross Profit Ratio | $0.76 | $0.57 | $0.81 | $0.79 |
| R&D Expenses | $21000.00 | $0.00 | $0.00 | $47000.00 |
| SG&A Expenses | $4.82M | $4.85M | $4.61M | $1.32M |
| Operating Expenses | $6.67M | $6.36M | $4.61M | $1.61M |
| Total Costs & Expenses | $9.54M | $11.49M | $6.58M | $2.71M |
| Interest Income | $0.00 | $0.00 | $0.00 | $611000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.82M | $1.51M | $1.93M | $292000.00 |
| EBITDA | $4.30M | $1.84M | $3.79M | $2.88M |
| EBITDA Ratio | $0.36 | $0.16 | $0.37 | $0.54 |
| Operating Income | $2.47M | $334000.00 | $3.79M | $2.88M |
| Operating Income Ratio | $0.21 | $0.03 | $0.37 | $0.54 |
| Other Income/Expenses (Net) | -$587000.00 | -$3.19M | -$1.54M | -$366000.00 |
| Income Before Tax | $1.89M | -$2.85M | $326000.00 | $2.52M |
| Income Before Tax Ratio | $0.16 | -$0.24 | $0.03 | $0.47 |
| Income Tax Expense | -$737000.00 | -$6.20M | $43000.00 | -$480000.00 |
| Net Income | $2.62M | $3.34M | $283000.00 | $3.00M |
| Net Income Ratio | $0.22 | $0.28 | $0.03 | $0.56 |
| EPS | $0.10 | $0.13 | $0.01 | $0.12 |
| Diluted EPS | $0.10 | $0.14 | $0.01 | $0.12 |
| Weighted Avg Shares Outstanding | $25.61M | $24.96M | $25.17M | $24.96M |
| Weighted Avg Shares Outstanding (Diluted) | $26.20M | $24.57M | $25.69M | $24.57M |
Over the last four quarters, Cipher Pharmaceuticals Inc. achieved steady financial progress, growing revenue from $5.30M in Q2 2024 to $12.02M in Q1 2025. Gross profit stayed firm with margins at 76% in Q1 2025 versus 79% in Q2 2024. Operating income totaled $2.47M in Q1 2025, maintaining a 21% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $4.30M. Net income dropped to $2.62M, with EPS at $0.10. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan